Open AccessClinical Efficacy of Corticosteroids in the Early Stages of Deterioration in COVID-19 Pneumonia
Author(s) -
Zheng Liu,
Fang Shi,
Junxia Liu,
Jiaqi Liu,
Jing Li,
Qian Wang,
Hui Wang,
Chang-Lan Gao,
Jianmin Li,
Dongfang Zhao
Publication year - 2021
Publication title -
infection and drug resistance
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.033
H-Index - 39
ISSN - 1178-6973
DOI - 10.2147/idr.s314938
Subject(s) - cytokine storm , medicine , pneumonia , covid-19 , dexamethasone , randomized controlled trial , corticosteroid , clinical trial , intensive care medicine , viral pneumonia , disease , infectious disease (medical specialty)
The World Health Organization (WHO) strongly suggests using corticosteroids in patients with severe coronavirus disease 2019 (COVID-19). Similarly, a large randomized controlled clinical trial (RCT) in the UK found that dexamethasone effectively reduced the mortality rate in severe COVID-19 patients. However, the safety profile of corticosteroids has been a controversial area of study.